|
Friday, December 9, 2022, 11:30 AM – 1:30 PM CT (12:30 PM – 2:30 PM ET) – New Orleans, Louisiana
Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia — What Clinicians Want to Know (Part 1 of a 3-Part Series)A CME Friday Satellite Symposium and Virtual Event Preceding the 64th ASH Annual Meeting
Location
Hyatt Regency New Orleans 601 Loyola Avenue New Orleans, LA 70113 Hotel Phone: (504) 561-1234 Program Schedule — Central Time 11:00 AM – 11:30 AM — Registration and Lunch 11:30 AM – 1:30 PM — Educational Meeting Meeting Room Celestin Ballroom ABCD (Level 3) This event will also be webcast live. Please see Registration tab for details. Faculty
Alexey V Danilov, MD, PhD Professor, Department of Hematology and Transplantation Co-Director, Toni Stephenson Lymphoma Center City of Hope National Medical Center Duarte, California Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Professor Dr Arnon P Kater, MD, PhD Dept of Hematology, Cancer Center Amsterdam University Medical Centers University of Amsterdam Amsterdam, Netherlands Lindsey Roeker, MD Assistant Attending Physician Memorial Sloan Kettering Cancer Center New York, New York Philip A Thompson, MB, BS Associate Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Central Time
11:00 AM – 11:30 AM — Registration and Lunch Buffet 11:30 AM – 1:30 PM — Educational Meeting MODULE 1: Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL) — Dr Danilov
MODULE 2: Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL — Prof Kater
MODULE 3: Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Davids
MODULE 4: Selection and Sequencing of Available Therapies for R/R Disease — Dr Thompson
MODULE 5: Promising Investigational Agents and Strategies — Dr Roeker
Target Audience
CME Credit Form Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Danilov — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, MorphoSys, Nurix Therapeutics Inc, Oncovalent Therapeutics, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, MEI Pharma Inc, Nurix Therapeutics Inc, Takeda Pharmaceuticals USA Inc. Dr Davids — Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Ono Pharmaceutical Co Ltd, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Verastem Inc; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Novartis, TG Therapeutics Inc, Verastem Inc. Prof Kater — Advisory Committee and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, LAVA Therapeutics NV, Roche Laboratories Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, LAVA Therapeutics NV, Link Immunotherapeutics Inc, Roche Laboratories Inc; Speakers Bureau: AbbVie Inc. Dr Roeker — Consulting Agreements: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: Aptos Biosciences, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sound Biologics; Stock Options/Ownership — Public Ineligible Company: Abbott Laboratories; Speaking Engagements: Curio Bioscience, DAVA Oncology; Travel Support: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Thompson — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly; Contracted Research: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Lilly.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. Location
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia. IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our onsite registration desk will be open at 11:00 AM CT on Friday, December 9th. If you are interested in attending, please visit our registration desk outside the Celestin Ballroom ABCD (Level 3) of the Hyatt Regency New Orleans hotel (601 Loyola Avenue).
Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting. LIVE WEBCAST registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
|